Qiming Venture Partners

Activity in this selectionpiper-sandler-merchant-banking-e8f17d25

By stage

Series A3

Undisclosed3

Series C+2

Series B1

Biotech6

Healthtech2

AI1

China7

Singapore1

United States1

9 in this selection

Aug 27

Develops oligonucleotide therapeutics targeting chronic hepatitis B

$120MSeries C

Role not disclosed

Apr 29

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

$50MSeries A+

Role not disclosed

Apr 19

Develops interventional therapies for pulmonary hypertension and heart failure

$100MStrategic

Role not disclosed

Apr 10

Develops extrahepatic RNA-targeting therapeutics

$54MSeries A

Role not disclosed

Apr 9

Develops next-generation cell therapies for oncology and immunology

$110MPre-IPO

Role not disclosed

Apr 3

Develops intelligent platform-driven macrocyclic peptide drug discovery

$150MSeries B

Role not disclosed